BRUSSELS, BELGIUM -- (MARKET WIRE) -- January 16, 2007 -- EC approves new indication for Keppra® as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in patients with Idiopathic Generalised Epilepsy The European Commission (EC) has approved Keppra® (levetiracetam), as adjunctive therapy for the treatment of primary generalised tonic-clonic (PGTC) seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy (IGE). This new indication represents the fifth EU approval for Keppra® in epilepsy, and the second EU approval for Keppra® in a generalised seizure type.
